Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Sjogren’s Syndrome Market size was valued at US$ 235.6 billion in 2023 and is poised to grow at a CAGR of 3.6% from 2024-2030. Sjogren's syndrome is an autoimmune condition that develops when the body’s immune system attacks the gland that produces moisture in the mouth, eyes, and other body parts resulting in dryness of the eyes and mouth due to inflammation and resultant pathology of the lacrimal and salivary glands. Up to 50% of those who are affected also experience extra-glandular involvement in other organs, including the joints, skin, lungs, GI tract, neurological system, and kidneys.
According to WHO, approximately 1% of the U.S. population is affected by Sjogren’s with 9 out of 10 patients being women. The treatment regimen generally includes local therapies like pilocarpine, and cevimeline and, systemic therapies like corticosteroids, hydroxychloroquine, and immunosuppressants. The increase in incidence of Sjogren’s syndrome, increased awareness of preventive attention and increased income among the population is currently driving the market.
The recent studies focussing on alternative strategies in molecular technology have produced a wide range of novel putative blood, salivary, and histologic biomarkers, increasing the opportunities for market development. The development of a robust drug pipeline during COVID-19 has presented huge opportunities for the development of several NSAIDs and hydroxychloroquine and is expected to have a significant impact on the Sjogren’s syndrome market. For instance, in January 2023, Horizon announced that Dazodalibep had achieved approval in 2nd phase and is currently undergoing 3rd phase. Based on key molecule type, the biologics segment is dominating the market owing to the extensive use of B-cell targeted therapies, therapies targeting various cytokines, chemokines, and Toll-like receptors.
However according to research conducted currently, no permanent cure is available, treatments only treat the symptoms or are viewed as ineffective by many patients. Moreover, tight government regulations, expensive treatment costs, and Sjogren's disease consequences including acute dehydration, considerable weight loss, and inflammation, slows down the market's expansion. However, a rise in awareness of preventive attention, an increase in disposable income among the population, developed infrastructure, and increased pharmaceutical and biotechnology industries have a significant positive effect on the market and are expected to burgeon in the forecast period.
Study Period
2024-2030Base Year
2023CAGR
3.6%Largest Market
North AmericaFastest Growing Market
North America
Growing incidence of sjogrens syndrome coupled with rising awareness the sjogrens syndrome are expected to drive the growth of sjogrens syndrome market. Furthermore, increase in patient pool with rheumatoid arthritis and lupus, environmental pollution, growing demand for the advanced treatments and therapies are expected to boost the growth of the sjogrens syndrome market. However, lack of awareness is a major drawback sjogrens syndrome market.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 235.6 billion |
Market CAGR |
3.6% |
By Drug |
|
By Type |
|
By Distribution Channel |
|
By Region |
|
Download Free Sample Report
The global sjogrens syndrome market size was valued at US$ 235.6 billion in 2023 and is projected to grow at a CAGR of 3.6% from 2024-2030.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
The sjogrens syndrome market key players are Allergan Inc. (Ireland) Auven Therapeutics (U.S.) Novartis AG (Switzerland) Santen Pharmaceutical Co. Ltd. (Japan) Otsuka Pharmaceutical Co., Ltd. (Japan) Argentis Pharmaceuticals, LLC. (UK)
1.Executive Summary |
2.Global Sjogrens Syndrome Market Introduction |
2.1.Global Sjogrens Syndrome Market - Taxonomy |
2.2.Global Sjogrens Syndrome Market - Definitions |
2.2.1. By Drug |
2.2.2. By Type |
2.2.3. By Distribution Channel |
2.2.4. By Region |
3.Global Sjogrens Syndrome Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Sjogrens Syndrome Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Sjogrens Syndrome Market By Drug , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Pilocarpine |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Cyclosporine |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. NSAIDS |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Hydroxychloroquine |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6.Global Sjogrens Syndrome Market By Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Primary Sjogrens Syndrome |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Secondary Sjogrens Syndrome |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7.Global Sjogrens Syndrome Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online pharmacies |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Sjogrens Syndrome Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Sjogrens Syndrome Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Drug Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Pilocarpine |
9.1.2.Cyclosporine |
9.1.3.NSAIDS |
9.1.4.Hydroxychloroquine |
9.2. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Primary Sjogrens Syndrome |
9.2.2.Secondary Sjogrens Syndrome |
9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital Pharmacies |
9.3.2.Retail Pharmacies |
9.3.3.Online pharmacies |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Sjogrens Syndrome Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Drug Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Pilocarpine |
10.1.2.Cyclosporine |
10.1.3.NSAIDS |
10.1.4.Hydroxychloroquine |
10.2. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Primary Sjogrens Syndrome |
10.2.2.Secondary Sjogrens Syndrome |
10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital Pharmacies |
10.3.2.Retail Pharmacies |
10.3.3.Online pharmacies |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Sjogrens Syndrome Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Drug Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Pilocarpine |
11.1.2.Cyclosporine |
11.1.3.NSAIDS |
11.1.4.Hydroxychloroquine |
11.2. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Primary Sjogrens Syndrome |
11.2.2.Secondary Sjogrens Syndrome |
11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital Pharmacies |
11.3.2.Retail Pharmacies |
11.3.3.Online pharmacies |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Sjogrens Syndrome Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Drug Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Pilocarpine |
12.1.2.Cyclosporine |
12.1.3.NSAIDS |
12.1.4.Hydroxychloroquine |
12.2. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Primary Sjogrens Syndrome |
12.2.2.Secondary Sjogrens Syndrome |
12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital Pharmacies |
12.3.2.Retail Pharmacies |
12.3.3.Online pharmacies |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Sjogrens Syndrome Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Drug Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Pilocarpine |
13.1.2.Cyclosporine |
13.1.3.NSAIDS |
13.1.4.Hydroxychloroquine |
13.2. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Primary Sjogrens Syndrome |
13.2.2.Secondary Sjogrens Syndrome |
13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital Pharmacies |
13.3.2.Retail Pharmacies |
13.3.3.Online pharmacies |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Allergan Inc. (Ireland) |
14.2.2.Auven Therapeutics (U.S.) |
14.2.3.Novartis AG (Switzerland) |
14.2.4.Santen Pharmaceutical Co. Ltd. (Japan) |
14.2.5.Otsuka Pharmaceutical Co., Ltd. (Japan) |
14.2.6.Argentis Pharmaceuticals, LLC. (UK) |
14.2.7.Nicox S.A. (France) |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players